QuidelOrtho reports Q3 2026 results and launches $80 million annual savings restructuring plan

QuidelOrtho Corp announced third‑quarter 2026 revenue of $619 million, down 12% year‑over‑year, with point‑of‑care sales falling 27% and China revenue dropping 45% due to new IVD pricing guidelines. The company launched a cost‑transformation and enterprise restructuring program that it expects to generate over $80 million in annual savings in 2027, accompanied by $30‑$35 million of one‑time restructuring charges in Q4 2026. Full‑year 2026 guidance was narrowed to $2.52‑$2.54 billion of revenue and $0.65‑$0.70 of adjusted diluted EPS.

The announced savings program should improve profitability and cash flow starting in 2027, while the narrowed guidance reduces the upside for investors and signals continued pressure from China and respiratory demand. The company’s adjusted EBITDA outlook was set at $540‑$545 million for the year.

  • 1Total Q3 2026 revenue was $619 million, a 12% decline both as reported and in constant currency.
  • 2Point‑of‑care revenue was $120 million, down 27% year‑over‑year.
  • 3China revenue fell 45% year‑over‑year due to IVD pricing changes.
  • 4The cost‑transformation and restructuring program is expected to deliver over $80 million in annual savings in 2027.
  • 5One‑time restructuring charges of approximately $30‑$35 million are expected in Q4 2026.
  • 6Full‑year 2026 revenue guidance was narrowed to $2.52‑$2.54 billion.

Sources